dalteparin has been researched along with Cardiac Remodeling, Ventricular in 1 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nahrendorf, M | 1 |
| Aikawa, E | 1 |
| Figueiredo, JL | 1 |
| Stangenberg, L | 1 |
| van den Borne, SW | 1 |
| Blankesteijn, WM | 1 |
| Sosnovik, DE | 1 |
| Jaffer, FA | 1 |
| Tung, CH | 1 |
| Weissleder, R | 1 |
1 other study available for dalteparin and Cardiac Remodeling, Ventricular
| Article | Year |
|---|---|
Transglutaminase activity in acute infarcts predicts healing outcome and left ventricular remodelling: implications for FXIII therapy and antithrombin use in myocardial infarction.
Topics: Animals; Anticoagulants; Collagen; Dalteparin; Factor XIII; Fibrinolytic Agents; Heart Rupture, Post | 2008 |